Fenofibrate Increases Radiosensitivity in Head and Neck Squamous Cell Carcinoma via Inducing G2/M Arrest and Apoptosis

Jia Liu, Yangyang Ge, Hongcheng Zhu, Xi Yang, Jing Cai, Chi Zhang, Jing Lü, Liangliang Zhan, Qin Qin, Yan Yang, Yuehua Yang, Hao Zhang, Xiaochen Chen, Zheming Liu, Jianxin Ma, Hongyan Cheng, Xinchen SunAsian 2014 · DOI

Abstract

Radiation therapy is a cornerstone of treatment for head and neck squamous cell carcinoma (HNSCC), yet therapeutic resistance remains a significant hurdle. This study investigates the potential of fenofibrate, a common lipid-lowering agent, as a radiosensitizer. Using HNSCC cell lines (CNE-2 and KB) and mouse xenograft models, researchers found that fenofibrate enhances radiation-induced cell death. The mechanism involves inducing G2/M phase arrest and apoptosis by downregulating the CDK1/cyclinB1 kinase complex. These findings suggest that fenofibrate could be repurposed to improve the efficacy of radiotherapy in HNSCC patients.

Introduction: The Challenge of Radioresistance in HNSCC

Head and neck squamous cell carcinoma (HNSCC) ranks as the sixth most common malignancy globally. While radiotherapy is a primary treatment modality, its clinical success is often hampered by the tumor's intrinsic resistance to ionizing radiation (IR) and the systemic toxicity associated with concurrent chemotherapy. Identifying effective "radiosensitizers"—agents that selectively increase the susceptibility of cancer cells to radiation—is a critical goal in oncology. This research explores whether Fenofibrate, a ligand for the peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$), can serve this role by modulating cell cycle progression and promoting programmed cell death.

Methodology

The study utilized a comprehensive experimental framework:

  • In Vitro Models: CNE-2 (nasopharyngeal carcinoma) and KB (oral epidermoid carcinoma) cell lines were treated with varying concentrations of Fenofibrate and doses of radiation.
  • Assays: Clonogenic survival assays determined long-term reproductive integrity. Flow cytometry analyzed cell cycle distribution (G2/M arrest) and apoptosis rates (Annexin V-FITC/PI staining).
  • Molecular Analysis: Western blotting quantified the expression of key regulatory proteins, specifically Cyclin B1 and CDK1. Caspase-3 activity was measured to confirm apoptotic signaling.
  • In Vivo Validation: CNE-2 cells were xenografted into BALB/c nude mice. The mice received combination therapy (Fenofibrate + 8Gy radiation) to evaluate tumor growth delay and doubling time in a physiological context.

Mechanism of Action: Targeting the G2/M Checkpoint

The study reveals that Fenofibrate's radiosensitizing effect is primarily driven by its impact on the cell cycle. Cells are most sensitive to radiation during the G2 and M phases. Fenofibrate acts as a molecular "brake," inducing G2/M phase arrest.

At the molecular level, Fenofibrate reduces the activity of the CDK1/Cyclin B1 kinase complex. This complex is essential for the transition from the G2 phase into mitosis. By inhibiting this "engine," Fenofibrate prevents cancer cells from progressing through the cycle, thereby trapping them in a vulnerable state where DNA damage from radiation is more likely to lead to cell death rather than repair.

Key Results

The experimental data demonstrated a clear synergistic effect between Fenofibrate and radiation:

  • Increased Radiosensitivity: The Sensitizing Enhancement Ratio (SER) was calculated at 1.42 for CNE-2 and 1.32 for KB cells, showing a significant boost in radiation efficacy.
  • Dose-Dependent Growth Inhibition: Fenofibrate alone inhibited cell growth in a time- and dose-dependent manner across both cell lines.
  • Enhanced Apoptosis: In KB cells, the combination of radiation and Fenofibrate increased Caspase-3 activity to 183.81%, significantly higher than radiation (149.01%) or Fenofibrate (112.01%) alone.
  • In Vivo Efficacy: In mouse models, the combination therapy resulted in a tumor response enhancement factor of 2.62, indicating that the laboratory findings translate effectively to living organisms.
Figure 5: Fenofibrate inhibits HNSCC cell growth and enhances radiosensitivity. (A-B) Survival rates of CNE-2 and KB cells treated with varying concentrations of FN. (C-D) Survival fraction curves showing the radiosensitizing effect of FN on CNE-2 and KB cells.

Conclusion and Future Directions

This study provides strong evidence that Fenofibrate can effectively radiosensitize HNSCC cells by inducing G2/M arrest and apoptosis via the downregulation of CDK1 and Cyclin B1. As an FDA-approved drug with a well-established safety profile, Fenofibrate is a promising candidate for drug repurposing in oncology.

However, further research is needed to:

  1. Map the precise upstream signaling pathways connecting PPAR$\alpha$ activation to CDK1/Cyclin B1 downregulation.
  2. Evaluate the interaction between Fenofibrate and the immune system in immunocompetent models, as "nude" mice lack a full immune response.
  3. Conduct clinical trials to establish optimal dosing regimens for human patients undergoing radiotherapy.

Summary updated

Abstract

Radiation therapy is an important treatment for head and neck squamous cell carcinoma (HNSCC). However, how to promote radiation sensitivity in HNSCC remains a challenge. This study aimed to investigate the radiosensitizing effects of fenofibrate on HNSCC and explore the underlying mechanisms. HNSCC cell lines CNE-2 and KB were subjected to ionizing radiation (IR), in the presence or absence of fenofibrate treatment. Cell growth and survival, apoptosis and cell cycle were evaluated. In addition, CNE-2 cells were xenografted into nude mice and subjected to IR and/ or fenofibrate treatment. The expression of cyclinB and CDK1 was detected by Western blotting. Our results showed that fenofibrate efficiently radiosensitized HNSCC cells and xenografts in mice, and induced apoptosis and G2/M arrest via reducing the activity of the CDK1/cyclinB1 kinase complex. These data suggest that fenofibrate could be a promising radiosensitizer for HNSCC radiotherapy.
BibTeX
@inproceedings{liu2014fenofibrate,
  author = {Jia Liu and Yangyang Ge and Hongcheng Zhu and Xi Yang and Jing Cai and Chi Zhang and Jing Lü and Liangliang Zhan and Qin Qin and Yan Yang and Yuehua Yang and Hao Zhang and Xiaochen Chen and Zheming Liu and Jianxin Ma and Hongyan Cheng and Xinchen Sun},
  title = {{Fenofibrate Increases Radiosensitivity in Head and Neck Squamous Cell Carcinoma via Inducing G2/M Arrest and Apoptosis}},
  booktitle = {Asian},
  year = {2014},
  doi = {10.7314/apjcp.2014.15.16.6649},
}
Figure